Sign in
CompletedPhase 3

Adalimumab vs. Conventional Immunosuppression for Uveitis Trial

Key facts

Who runs it
JHSPH Center for Clinical Trials
Where
Ann Arbor, Atlanta, Baltimore, Bellaire, Bethesda, Boston, Chicago, Iowa City, Los Angeles, Miami, Nashville, Philadelphia, Pittsburgh, Salt Lake City, San Francisco, Seattle, and St Louis, United StatesSee the 19 sitesAlso in 2 other countries, 7 sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
227 people enrolled
Started
16 Sept 2019
Ended
9 Sept 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Adalimumab (ADA)
  • Conventional immunosuppression (CON)
Record updated
16 May 2025

Who can take part

Age
13 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 31 criteriaShow less

Who can take part

  • Age 13 years or older
  • Weight 30 kg (66 lbs) or greater
  • Active or recently active (≤ 60 days) non-infectious intermediate, posterior, or panuveitis
  • Prednisone indication meets one of the following:; Active uveitis requiring one of the following i. Initiation of prednisone at dose greater than 7.5 mg/day ii. Increasing prednisone dose to greater than 7.5 mg/day iii. Currently receiving dose greater than 7.5 mg/day; Inactive uveitis on current dose greater 7.5 mg/day
  • Initiation or addition of an immunosuppressive drug (i.e., a conventional immunosuppressive drug or adalimumab) is indicated
  • If currently receiving a conventional immunosuppressive drug, the drug and dose have been stable for at least 30 days
  • Patient able and willing to self-administer subcutaneous injections or have a qualified person available to administer subcutaneous injections
  • If posterior segment disease is present, ability to assess activity in at least one eye with uveitis
  • Visual acuity of light perception or better in at least one eye with uveitis

Who cannot take part

  • Receipt of a live vaccine within past 30 days
  • Use of anti-TNF monoclonal antibody therapy within past 60 days
  • Current treatment with an alkylating agent
  • Current treatment with more than one immunosuppressive drug, not including oral corticosteroids
  • Shorter-acting regional corticosteroids administered within the past 30 days in any eye(s) with uveitis
  • Long-acting ocular corticosteroid implants, i.e., fluocinolone acetonide implant (e.g., Retisert®, Yutiq™, Iluvien®) placed within past 3 years unless uveitis is active in all eye(s) with an implant
  • For persons of child-bearing potential or impregnating potential, unwillingness to use appropriate birth control (abstinence, combination barrier and spermicide, hormonal, or intrauterine device) for the next 18 months or plans to become a biological parent within the next 18 months; In the United Kingdom (UK), use of combination barrier and spermicide alone does not meet birth control requirements; † UK female study participants must use highly effective methods of contraception; UK male study participants must use condoms for at least 6 months after the end of study treatment and their female partners of child-bearing potential are recommended to use highly effective contraception for the same duration. In addition, male participants should not donate semen during therapy or for 6 months following discontinuation of study treatment
  • Medical problems or drug or alcohol dependence problems sufficient to prevent adherence to treatment and study procedures
  • Active tuberculosis or untreated latent tuberculosis (e.g., positive interferon-γ release assay [Interferon-gamma release assay (IGRA) test, such as Quantiferon-gold)
  • Untreated active hepatitis B or C infection
  • Behçet disease
  • Multiple sclerosis or other demyelinating disease
  • For patients with anterior/intermediate or intermediate uveitis without systemic disease, abnormal magnetic resonance imaging (MRI) of the brain consistent with demyelinating disease
  • Severe uncontrolled infection
  • Moderate to severe heart failure (NYHA class III/IV)
  • Active malignancy
  • History of adalimumab intolerance or ineffectiveness
  • Hypersensitivity to any of the study treatments or their excipients
  • Systemic disease that is sufficiently active such that it dictates therapy with systemic corticosteroids or immunosuppressive agents at the time of enrollment
  • Immunodeficiency disease for which immunosuppressive therapy would be contraindicated according to best medical judgment
  • Any of the following baseline lab values; White blood count <3500 cells per microliter; Platelets <100,000 per microliter; Hematocrit <30%; aspartate aminotransferase (AST) or alanine transaminase (ALT) >1.5 times (X) upper limit normal value; Serum creatinine >1.1 times (X) upper limit normal value
  • Pregnancy or lactation

Where in United States

Also in 2 other countries, 7 sites

  • University of Michigan Health System, Kellogg Eye CenterAnn Arbor, United States
  • Emory UniversityAtlanta, United States
  • Johns Hopkins UniversityBaltimore, United States
  • Retinal Consultants of TexasBellaire, United States
  • National Eye InstituteBethesda, United States
  • Ophthalmic Consultants of BostonBoston, United States
  • Northwestern UniversityChicago, United States
  • Rush University Medical CenterChicago, United States
  • University of IowaIowa City, United States
  • Jules Stein Eye Institute/ UCLALos Angeles, United States
  • Anne Bates Leach Eye Hospital, University of Miami Miller School of MedicineMiami, United States
  • Tennessee RetinaNashville, United States
  • Vanderbilt University Eye InstituteNashville, United States
  • MidAtlantic Retina, Wills Eye HospitalPhiladelphia, United States
  • University of Pittsburgh Medical CenterPittsburgh, United States
  • University of Utah, Moran Eye CenterSalt Lake City, United States
  • University of California San FranciscoSan Francisco, United States
  • University of Washington, Medicine Eye InstituteSeattle, United States
  • Washington UniversitySt Louis, United States

About the trial

What the trial wants to find out

Non-infectious intermediate, posterior, and panuveitides are chronic, potentially-blinding diseases. Vision-threatening cases require long-term therapy with oral corticosteroids and immunosuppression. Based upon preliminary data, adalimumab, a fully-human, anti-tumor necrosis(TNF)-α monoclonal antibody, now US FDA-approved for uveitis treatment, may be a superior corticosteroid-sparing agent than conventional immunosuppressive drugs. The ADVISE Trial is multicenter randomized, parallel-treatment, comparative effectiveness trial comparing adalimumab to conventional (small molecule) immunosuppression for corticosteroid spring in the treatment of non-infectious, intermediate, posterior, and panuveitides.

The 2 groups in the trial

  • Adalimumab (ADA)Existing treatment, for comparison

    Adalimumab administered by subcutaneous injection at dosage and frequency specified below; total duration of treatment is 12 months. Adults (≥ 18 years of age) and adolescents ≥30 kg: 80 mg as initial dose; one week later by 40 mg then 40 mg every two weeks. Adolescents \<30 kg: 40 mg as initial dose; one week later 20 mg then 20 mg every 2 weeks.

  • Conventional immunosuppression (CON)Existing treatment, for comparison

    Conventional immunosuppressive agent selected by study ophthalmologist at dose and frequency specified below;12 month treatment duration. Azathioprine: initially 2 mg/kg/day; max dose 200 mg/day. Methotrexate initially 15mg/wk; max dose 25 mg/wk. Mycophenolate initially 1 gm twice daily (BID); max dose1.5 gm BID. Cyclosporine (Sandimmune - dose 2.5 mg/kg BID and Neoral dose 2 mg/kg BID. Tacrolimus initially 1 mg BID; max dose 3 mg BID.

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
16 May 2025